ONDINE BIOMEDICAL INC. - Investor Presentation of Phase 3 Topline Results

In this episode, we explore a groundbreaking technology from Ondine Biomedical that aims to tackle surgical site infections using an innovative method involving lasers. The approach employs a cold, photosensitive compound activated by red laser light, which disrupts the cellular structure of harmful pathogens in just four minutes. Initial data from a Phase 3 study across 18 hospitals shows a significant 40.5% reduction in surgical infections, suggesting a compelling alternative to traditional antibiotic methods. Key benefits include a low side effect profile and potential applications beyond surgical settings, including intensive care units. This development could signal a shift toward physics-based therapies in infection control, challenging the current reliance on chemical antibiotics.